Kavitha Pandy Raj, MD
Hematology/Oncology · Pleasanton
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: San Ramon Regional Medical Center · Stanford Health Care · Stanford Health Care Tri-Valley · Washington Hospital. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Raj’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A93219 · Current
Licensed to practise in California · since 2005 · expires 2027-11-30 · Dr. M. G. R. University, Kilpauk Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- San Ramon Regional Medical CenterSan Ramon, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Tenet Healthcare, which runs 77 hospitals in 12 statesPatients rate it 3 of 5 · 65% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
- Washington HospitalFremont, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Washington Hospital Healthcare SystemPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.188, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.164, Oct 2024 – Sep 2025
See every measure and the patient survey for San Ramon Regional Medical Center
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 0 better, 4 the same, 0 worse of 4 measures. Readmissions: 0 better, 7 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.94 (0 to 1.97) · 507 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.83 (0.44 to 1.22) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.1 · 36 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 87 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.2 · 195 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.7 · 284 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 63 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,118 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 2,515 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.29 (0.08 to 0.49) · 2,618 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.62 (1.26 to 5.98) · 588 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0 to 3.14) · 282 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.34 (0.72 to 3.97) · 598 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.12 (0.84 to 15.4) · 258 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.08 (0.25 to 7.91) · 225 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.02 (0.52 to 3.52) · 241 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.29) · 2,110 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 73 cases | None | Apr 2023 – Mar 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.553 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.104 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 84 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 186 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 39.6 · 79 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -10.3 · 227 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -5.2 · 305 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 314 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.9 · 84 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 37 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.4 to 17.3) · 86 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 256 cases | No different | Jan 2024 – Dec 2024 |
What patients said (642 patients answered, 25% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 65% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 65% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Washington Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 6 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.188 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.164 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.88) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.59 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.95 (139.54 to 246.36) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 164 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 199 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 661 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 174 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 2,550 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.35) · 6,970 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,108 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.82 (1.73 to 5.91) · 1,370 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.52 (0 to 3.17) · 589 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.75 (0.25 to 3.25) · 1,315 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.19 (5.83 to 20.56) · 600 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.91 (1.04 to 8.78) · 550 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.14) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 6,079 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 114 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.367 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 480 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 33.9 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.5 · 553 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.8 · 648 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 590 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.2 to 6.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.5 to 14.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 130 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.1 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 202 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.7 (10.2 to 18.5) · 78 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 974 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$551,174
Medicare paid this office $551,174 for 957 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 855 | $211,806 | $111 |
| New patient visit (60+ min) | 123 | $22,926 | $186 |
| Long return visit (40+ min) | 79 | $16,053 | $164 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 540 | $11,196 | $15 |
| Administration of chemotherapy into vein, 1 hour or less | 33 | $7,983 | $138 |
See all 22 services
| Return visit (30+ min) | 855 | $211,806 | $111 |
| New patient visit (60+ min) | 123 | $22,926 | $186 |
| Long return visit (40+ min) | 79 | $16,053 | $164 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 540 | $11,196 | $15 |
| Administration of chemotherapy into vein, 1 hour or less | 33 | $7,983 | $138 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $5,181 | $152 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $4,930 | $105 |
| Short return visit (20+ min) | 49 | $4,115 | $73 |
| Telephone medical discussion with physician, 11-20 minutes | 26 | $2,173 | $78 |
| Administration of additional new drug or substance into vein, 1 hour or less | 14 | $1,927 | $66 |
| Injection of additional new drug or substance into vein | 28 | $1,694 | $16 |
| Drawing of blood for a medical problem | 12 | $1,497 | $100 |
| Telephone medical discussion with physician, 5-10 minutes | 25 | $1,337 | $51 |
| Administration of chemotherapy into vein, each additional hour | 18 | $854 | $28 |
| Irrigation of implanted venous access drug delivery device | 20 | $841 | $25 |
| Insertion of needle into vein for collection of blood sample | 68 | $640 | $9 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 53 | $540 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 14 | $516 | $29 |
| Injection, palonosetron hcl, 25 mcg | 22 | $258 | None |
| Injection, fosaprepitant, 1 mg | 12 | $215 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 25 | $38 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 18 | $17 | None |
Who their Medicare patients are
957 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 16% · Women 74% · Also on Medicaid 15% · Health risk score 1.65. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 73% · Cancer 57% · Chronic kidney disease 35% · Diabetes 28% · Coronary heart disease 25% · Depression 19% · Atrial fibrillation 18% · COPD 17% · Heart failure 16% · Dementia 6% · Stroke 6%.
The office billed $2,554,758, Medicare allowed $720,605 and paid $551,174; for 21,432 services of 90 kinds; $249,975 of it was for drugs given in the office and $301,199 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 957 | 21,432 | 76 | 1.65 | $2,554,758 | $551,174 |
| 2023 | 924 | 67,228 | 76 | 1.63 | $6,545,079 | $1,406,233 |
| 2022 | 884 | 123,025 | 76 | 1.65 | $7,261,959 | $1,624,974 |
| 2021 | 879 | 164,155 | 75 | 1.61 | $9,892,948 | $2,196,948 |
| 2020 | 782 | 196,593 | 76 | 1.83 | $14,676,105 | $3,199,821 |
| 2019 | 861 | 244,691 | 76 | 1.85 | $12,389,307 | $2,846,731 |
| 2018 | 816 | 282,262 | 75 | 1.92 | $12,485,029 | $3,066,021 |
| 2017 | 795 | 324,092 | 75 | 1.84 | $13,350,424 | $3,133,640 |
| 2016 | 702 | 234,967 | 75 | 1.81 | $8,086,578 | $2,472,371 |
| 2015 | 631 | 250,666 | 76 | 1.79 | $8,938,734 | $2,838,396 |
| 2014 | 634 | 218,884 | 75 | 1.70 | $8,404,873 | $2,617,119 |
| 2013 | 603 | 134,897 | 75 | 1.82 | $6,152,642 | $2,035,488 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 37 services
| Injection, pembrolizumab, 1 mg | 15 | $163,697 | None |
| Return visit (30+ min) | 713 | $148,686 | $109 |
| Injection, denosumab, 1 mg | 14 | $34,244 | None |
| New patient visit (60+ min) | 146 | $28,343 | $194 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 24 | $26,830 | None |
| Short return visit (20+ min) | 233 | $23,924 | $77 |
| Administration of chemotherapy into vein, 1 hour or less | 73 | $23,216 | $137 |
| Long return visit (40+ min) | 99 | $20,650 | $161 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $4,903 | $77 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $4,535 | $105 |
| Injection of additional new drug or substance into vein | 59 | $4,448 | $16 |
| Administration of additional new drug or substance into vein, 1 hour or less | 29 | $3,576 | $67 |
| New patient visit (45+ min) | 23 | $3,287 | $143 |
| Drawing of blood for a medical problem | 11 | $2,958 | $99 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $2,767 | $154 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 151 | $2,711 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 31 | $2,684 | $62 |
| Administration of chemotherapy into vein, each additional hour | 26 | $2,669 | $29 |
| Telephone medical discussion with physician, 11-20 minutes | 19 | $1,419 | $65 |
| Injection of drug or substance under skin or into muscle | 57 | $1,413 | $13 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $1,396 | $35 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 26 | $1,335 | $30 |
| Telephone medical discussion with physician, 5-10 minutes | 28 | $1,082 | $36 |
| Irrigation of implanted venous access drug delivery device | 24 | $1,068 | $24 |
| Injection, zoledronic acid, 1 mg | 28 | $1,016 | None |
| Infusion into a vein for hydration, 31-60 minutes | 14 | $812 | $32 |
| Injection of drug or substance into vein | 19 | $734 | $39 |
| Injection, fosaprepitant, 1 mg | 21 | $683 | None |
| Injection, palonosetron hcl, 25 mcg | 37 | $626 | None |
| Injection, paclitaxel, 1 mg | 12 | $553 | None |
| Application of on-body injector for under skin injection | 21 | $481 | $19 |
| Infusion into a vein for hydration, each additional hour | 16 | $336 | $12 |
| Injection, carboplatin, 50 mg | 15 | $304 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 47 | $119 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 39 | $71 | None |
| Automated urinalysis test | 11 | $45 | $2 |
| Injection, ondansetron hydrochloride, per 1 mg | 13 | $13 | None |
2022: 44 services
| Return visit (30+ min) | 676 | $149,267 | $113 |
| Injection, denosumab, 1 mg | 26 | $63,184 | None |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 21 | $46,624 | None |
| Administration of chemotherapy into vein, 1 hour or less | 75 | $36,994 | $142 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 18 | $29,765 | None |
| New patient visit (60+ min) | 128 | $25,896 | $202 |
| Short return visit (20+ min) | 252 | $24,221 | $73 |
| Injection, ferric carboxymaltose, 1 mg | 23 | $22,637 | None |
| Long return visit (40+ min) | 96 | $21,925 | $167 |
| Injection, fulvestrant, 25 mg | 12 | $7,658 | None |
| Injection of additional new drug or substance into vein | 63 | $7,631 | $16 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $6,899 | $177 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 52 | $5,637 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $4,924 | $91 |
| Administration of additional new drug or substance into vein, 1 hour or less | 25 | $4,861 | $69 |
| Administration of chemotherapy into vein, each additional hour | 34 | $4,396 | $30 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 232 | $4,257 | $8 |
| New patient visit (45+ min) | 28 | $3,939 | $141 |
| Administration of chemotherapy into vein using push technique | 11 | $3,541 | $107 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 21 | $3,229 | $34 |
| Injection of drug or substance under skin or into muscle | 87 | $2,875 | $13 |
| Telephone medical discussion with physician, 11-20 minutes | 27 | $2,733 | $74 |
| Drawing of blood for a medical problem | 12 | $2,732 | $105 |
| Telephone medical discussion with physician, 5-10 minutes | 45 | $2,438 | $41 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 27 | $1,804 | $31 |
| Insertion of needle into vein for collection of blood sample | 201 | $1,259 | $3 |
| Infusion into a vein for hydration, each additional hour | 27 | $1,188 | $13 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,150 | $64 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 15 | $1,139 | $21 |
| Irrigation of implanted venous access drug delivery device | 27 | $1,119 | $24 |
| Administration of additional new drug or substance into vein using push technique | 11 | $1,071 | $60 |
| Infusion into a vein for hydration, 31-60 minutes | 18 | $983 | $34 |
| Injection, fosaprepitant, 1 mg | 23 | $922 | None |
| Injection, palonosetron hcl, 25 mcg | 39 | $908 | None |
| Application of on-body injector for under skin injection | 21 | $854 | $19 |
| Injection of drug or substance into vein | 17 | $726 | $38 |
| Injection, zoledronic acid, 1 mg | 21 | $611 | None |
| Injection, carboplatin, 50 mg | 11 | $537 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 49 | $218 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 40 | $98 | None |
| Infusion, normal saline solution , 1000 cc | 13 | $78 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 12 | $28 | None |
| Injection, magnesium sulfate, per 500 mg | 11 | $25 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 13 | $14 | None |
2021: 48 services
| Injection, trastuzumab, excludes biosimilar, 10 mg | 12 | $215,304 | None |
| Injection, pegfilgrastim, 6 mg | 31 | $166,249 | None |
| Injection, pembrolizumab, 1 mg | 14 | $163,846 | None |
| Return visit (30+ min) | 649 | $152,197 | $115 |
| Injection, rituximab, 10 mg | 12 | $134,895 | None |
| Injection, denosumab, 1 mg | 34 | $117,838 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 22 | $55,879 | None |
| Administration of chemotherapy into vein, 1 hour or less | 89 | $54,718 | $154 |
| New patient visit (60+ min) | 179 | $37,507 | $210 |
| Injection, fulvestrant, 25 mg | 12 | $37,218 | None |
| Injection, ferric carboxymaltose, 1 mg | 32 | $34,133 | None |
| Short return visit (20+ min) | 247 | $31,854 | $82 |
| Long return visit (40+ min) | 109 | $24,563 | $169 |
| Injection of additional new drug or substance into vein | 75 | $11,224 | $17 |
| Administration of additional new drug or substance into vein, 1 hour or less | 42 | $9,987 | $75 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $8,947 | $183 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 57 | $7,072 | $77 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 319 | $6,612 | $8 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $6,085 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $5,788 | $95 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 27 | $5,439 | $33 |
| Telephone medical discussion with physician, 11-20 minutes | 60 | $5,132 | $72 |
| Administration of chemotherapy into vein, each additional hour | 30 | $4,239 | $32 |
| Injection of drug or substance under skin or into muscle | 93 | $3,940 | $14 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 33 | $2,885 | $33 |
| Insertion of needle into vein for collection of blood sample | 352 | $2,823 | $3 |
| Telephone medical discussion with physician, 5-10 minutes | 43 | $2,702 | $48 |
| Injection, palonosetron hcl, 25 mcg | 47 | $2,306 | None |
| Injection, fosaprepitant, 1 mg | 23 | $2,079 | None |
| Infusion into a vein for hydration, 31-60 minutes | 18 | $1,835 | $37 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,630 | $65 |
| New patient visit (45+ min) | 11 | $1,573 | $143 |
| Application of on-body injector for under skin injection | 28 | $1,549 | $20 |
| Telephone medical discussion with physician, 21-30 minutes | 13 | $1,494 | $107 |
| Administration of additional new drug or substance into vein using push technique | 11 | $1,292 | $65 |
| Irrigation of implanted venous access drug delivery device | 24 | $1,249 | $28 |
| Injection, docetaxel, 1 mg | 11 | $1,249 | None |
| Infusion into a vein for hydration, each additional hour | 23 | $1,176 | $14 |
| Injection, zoledronic acid, 1 mg | 25 | $1,107 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 13 | $1,061 | None |
| Injection, paclitaxel, 1 mg | 11 | $987 | None |
| Injection of drug or substance into vein | 16 | $738 | $43 |
| Injection, carboplatin, 50 mg | 18 | $701 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 58 | $301 | None |
| Infusion, normal saline solution , 1000 cc | 24 | $179 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 56 | $124 | None |
| Automated urinalysis test | 13 | $56 | $2 |
| Injection, ondansetron hydrochloride, per 1 mg | 17 | $45 | None |
2020: 49 services
| Injection, pembrolizumab, 1 mg | 11 | $296,747 | None |
| Injection, trastuzumab, excludes biosimilar, 10 mg | 11 | $230,584 | None |
| Injection, rituximab, 10 mg | 16 | $194,345 | None |
| Injection, pegfilgrastim, 6 mg | 21 | $188,476 | None |
| Injection, denosumab, 1 mg | 31 | $127,164 | None |
| Return visit (30+ min) | 520 | $107,162 | $94 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 23 | $82,435 | None |
| Administration of chemotherapy into vein, 1 hour or less | 93 | $66,706 | $148 |
| Short return visit (20+ min) | 206 | $27,656 | $69 |
| Injection, ferric carboxymaltose, 1 mg | 18 | $20,511 | None |
| Long return visit (40+ min) | 97 | $18,214 | $134 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 15 | $17,405 | None |
| New patient visit (60+ min) | 86 | $16,487 | $192 |
| Injection of additional new drug or substance into vein | 88 | $13,937 | $17 |
| Telephone medical discussion with physician, 21-30 minutes | 88 | $11,623 | $101 |
| Telephone medical discussion with physician, 11-20 minutes | 130 | $11,519 | $71 |
| Injection, fosaprepitant, 1 mg | 24 | $10,614 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $9,972 | $95 |
| Administration of additional new drug or substance into vein, 1 hour or less | 32 | $9,230 | $72 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 45 | $8,971 | $183 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 376 | $8,901 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 40 | $6,807 | $74 |
| Injection, palonosetron hcl, 25 mcg | 43 | $5,920 | None |
| Administration of chemotherapy into vein, each additional hour | 33 | $5,488 | $31 |
| Injection of drug or substance under skin or into muscle | 98 | $5,437 | $13 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $4,380 | $31 |
| Insertion of needle into vein for collection of blood sample | 423 | $3,719 | $3 |
| Administration of chemotherapy into vein using push technique | 11 | $3,534 | $114 |
| Administration of additional new drug or substance into vein using push technique | 16 | $3,138 | $62 |
| Drawing of blood for a medical problem | 11 | $2,750 | $102 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 30 | $2,475 | $32 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $2,001 | $67 |
| New patient visit (45+ min) | 12 | $1,851 | $154 |
| Irrigation of implanted venous access drug delivery device | 39 | $1,783 | $27 |
| Infusion into a vein for hydration, 31-60 minutes | 19 | $1,624 | $35 |
| Extended office or other outpatient service, first hour | 11 | $1,310 | $119 |
| Application of on-body injector for under skin injection | 22 | $1,196 | $20 |
| Injection, carboplatin, 50 mg | 20 | $929 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 12 | $858 | None |
| Injection of drug or substance into vein | 13 | $817 | $41 |
| Injection, paclitaxel, 1 mg | 11 | $750 | None |
| Injection, zoledronic acid, 1 mg | 12 | $710 | None |
| Infusion into a vein for hydration, each additional hour | 16 | $469 | $14 |
| Injection, dexamethasone sodium phosphate, 1 mg | 72 | $324 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 64 | $162 | None |
| Infusion, normal saline solution , 1000 cc | 18 | $124 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 12 | $116 | $6 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $41 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 18 | $22 | None |
2019: 46 services
| Injection, denosumab, 1 mg | 44 | $199,080 | None |
| Injection, rituximab, 10 mg | 11 | $173,945 | None |
| Injection, pegfilgrastim, 6 mg | 19 | $153,360 | None |
| Return visit (30+ min) | 652 | $148,421 | $97 |
| Injection, bortezomib, 0.1 mg | 14 | $116,856 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 25 | $113,737 | None |
| Administration of chemotherapy into vein, 1 hour or less | 93 | $58,183 | $143 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 27 | $47,280 | None |
| Short return visit (20+ min) | 181 | $29,311 | $68 |
| Injection, ferric carboxymaltose, 1 mg | 24 | $26,131 | None |
| New patient visit (60+ min) | 126 | $23,445 | $186 |
| Long return visit (40+ min) | 106 | $19,073 | $134 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 71 | $18,555 | $94 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 667 | $18,004 | $8 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 61 | $12,034 | $182 |
| Injection, palonosetron hcl, 25 mcg | 46 | $9,373 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $9,219 | $82 |
| Injection of additional new drug or substance into vein | 83 | $8,727 | $17 |
| Injection of drug or substance under skin or into muscle | 127 | $7,499 | $16 |
| Administration of additional new drug or substance into vein, 1 hour or less | 34 | $6,997 | $71 |
| Administration of chemotherapy into vein using push technique | 12 | $5,075 | $110 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 40 | $4,245 | $30 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 22 | $4,107 | $72 |
| Administration of chemotherapy into vein, each additional hour | 27 | $3,926 | $31 |
| Administration of additional new drug or substance into vein using push technique | 17 | $2,904 | $60 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 18 | $2,840 | $31 |
| Insertion of needle into vein for collection of blood sample | 482 | $2,793 | $3 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 12 | $2,708 | None |
| Drawing of blood for a medical problem | 18 | $2,628 | $105 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $2,623 | $66 |
| Irrigation of implanted venous access drug delivery device | 46 | $2,387 | $27 |
| Injection of drug or substance into vein | 41 | $2,328 | $40 |
| Infusion into a vein for hydration, 31-60 minutes | 29 | $2,188 | $38 |
| Injection, carboplatin, 50 mg | 25 | $1,095 | None |
| Injection, paclitaxel, 1 mg | 19 | $1,035 | None |
| Injection, zoledronic acid, 1 mg | 13 | $962 | None |
| Application of on-body injector for under skin injection | 12 | $547 | $20 |
| Infusion into a vein for hydration, each additional hour | 16 | $435 | $13 |
| Injection, ranitidine hydrochloride, 25 mg | 25 | $395 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 71 | $241 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 16 | $197 | $7 |
| Infusion, normal saline solution , 1000 cc | 29 | $118 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 47 | $77 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 19 | $68 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 22 | $64 | None |
| Not otherwise classified, antineoplastic drugs | 13 | $22 | None |
2018: 44 services
| Injection, pegfilgrastim, 6 mg | 26 | $338,825 | None |
| Injection, denosumab, 1 mg | 50 | $230,406 | None |
| Return visit (30+ min) | 651 | $155,264 | $92 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 32 | $132,818 | None |
| Administration of chemotherapy into vein, 1 hour or less | 78 | $66,170 | $145 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 28 | $65,136 | None |
| Injection, ferric carboxymaltose, 1 mg | 31 | $34,349 | None |
| Short return visit (20+ min) | 144 | $34,222 | $64 |
| New patient visit (60+ min) | 131 | $23,639 | $180 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 638 | $23,098 | $9 |
| Injection, palonosetron hcl, 25 mcg | 38 | $20,718 | None |
| Long return visit (40+ min) | 111 | $19,613 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 88 | $17,787 | $93 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $12,826 | $81 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 68 | $12,199 | $179 |
| Injection of additional new drug or substance into vein | 69 | $11,072 | $18 |
| Injection of drug or substance under skin or into muscle | 125 | $10,127 | $19 |
| Administration of additional new drug or substance into vein, 1 hour or less | 31 | $8,312 | $69 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 50 | $7,676 | $31 |
| Administration of chemotherapy into vein, each additional hour | 27 | $6,615 | $31 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 20 | $6,376 | $74 |
| Infusion into a vein for hydration, 31-60 minutes | 28 | $4,389 | $47 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 18 | $3,989 | None |
| Injection of drug or substance into vein | 46 | $3,729 | $47 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $3,207 | $30 |
| Drawing of blood for a medical problem | 17 | $3,090 | $107 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $2,911 | $65 |
| Irrigation of implanted venous access drug delivery device | 37 | $2,890 | $26 |
| Aspiration of bone marrow sample for diagnosis | 17 | $2,799 | $165 |
| Application of on-body injector for under skin injection | 25 | $1,700 | $20 |
| Injection, alteplase recombinant, 1 mg | 11 | $1,609 | None |
| Injection, zoledronic acid, 1 mg | 18 | $1,505 | None |
| Biopsy of bone marrow | 17 | $1,290 | $76 |
| Injection, carboplatin, 50 mg | 15 | $1,229 | None |
| Injection, paclitaxel, 1 mg | 13 | $1,162 | None |
| Injection, ranitidine hydrochloride, 25 mg | 26 | $778 | None |
| Infusion into a vein for hydration, each additional hour | 16 | $452 | $14 |
| Injection, dexamethasone sodium phosphate, 1 mg | 60 | $316 | None |
| Infusion, normal saline solution , 1000 cc | 26 | $166 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 41 | $96 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 18 | $71 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 18 | $55 | None |
| Not otherwise classified, antineoplastic drugs | 15 | $25 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 12 | $19 | None |
2017: 49 services
| Injection, pegfilgrastim, 6 mg | 38 | $465,108 | None |
| Injection, denosumab, 1 mg | 52 | $227,513 | None |
| Injection, rituximab, 100 mg | 13 | $222,860 | None |
| Return visit (30+ min) | 630 | $161,562 | $93 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 33 | $159,871 | None |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 32 | $78,996 | None |
| Administration of chemotherapy into vein, 1 hour or less | 87 | $62,037 | $137 |
| Injection, ferric carboxymaltose, 1 mg | 39 | $36,219 | None |
| Injection, palonosetron hcl, 25 mcg | 52 | $34,652 | None |
| Short return visit (20+ min) | 162 | $34,055 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 101 | $29,821 | $91 |
| New patient visit (60+ min) | 157 | $28,355 | $181 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 625 | $25,541 | $10 |
| Not otherwise classified, antineoplastic drugs | 46 | $21,613 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 84 | $18,927 | $30 |
| Injection of drug or substance under skin or into muscle | 139 | $16,938 | $24 |
| Cyclophosphamide, 100 mg | 11 | $16,727 | None |
| Long return visit (40+ min) | 79 | $13,757 | $129 |
| Administration of additional new drug or substance into vein, 1 hour or less | 39 | $10,881 | $64 |
| Infusion into a vein for hydration, 31-60 minutes | 42 | $10,179 | $58 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $10,102 | $73 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 53 | $9,915 | $177 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 32 | $8,057 | $68 |
| Injection, docetaxel, 1 mg | 11 | $7,668 | None |
| Injection of additional new drug or substance into vein | 69 | $7,145 | $22 |
| Administration of chemotherapy into vein, each additional hour | 34 | $5,896 | $27 |
| Drawing of blood for a medical problem | 19 | $5,233 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $4,997 | $63 |
| Administration of additional new drug or substance into vein using push technique | 15 | $4,017 | $62 |
| Injection of drug or substance into vein | 50 | $3,865 | $57 |
| Aspiration of bone marrow sample for diagnosis | 20 | $3,268 | $163 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 12 | $2,267 | None |
| Irrigation of implanted venous access drug delivery device | 31 | $2,163 | $24 |
| Injection, carboplatin, 50 mg | 24 | $2,038 | None |
| Injection, paclitaxel, 1 mg | 18 | $1,781 | None |
| Biopsy of bone marrow | 20 | $1,630 | $82 |
| Injection, alteplase recombinant, 1 mg | 11 | $1,495 | None |
| Infusion into a vein for hydration, each additional hour | 32 | $1,291 | $15 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 11 | $1,199 | $17 |
| Injection, zoledronic acid, 1 mg | 14 | $863 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 14 | $594 | $20 |
| Insertion of needle into vein for collection of blood sample | 117 | $395 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 73 | $349 | None |
| Infusion, normal saline solution , 1000 cc | 42 | $300 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 61 | $152 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 16 | $127 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 24 | $66 | None |
| Stool analysis for blood to screen for colon tumors | 12 | $52 | $4 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 13 | $24 | None |
2016: 42 services
| Injection, pegfilgrastim, 6 mg | 31 | $425,083 | None |
| Injection, denosumab, 1 mg | 40 | $151,334 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 30 | $141,316 | None |
| Return visit (30+ min) | 528 | $131,103 | $88 |
| Administration of chemotherapy into vein, 1 hour or less | 59 | $47,323 | $130 |
| Short return visit (20+ min) | 188 | $44,046 | $63 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 19 | $42,359 | None |
| Injection, palonosetron hcl, 25 mcg | 41 | $34,370 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 102 | $26,977 | $89 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 539 | $23,594 | $10 |
| New patient visit (60+ min) | 117 | $20,534 | $176 |
| Long return visit (40+ min) | 97 | $18,334 | $125 |
| Injection, ferric carboxymaltose, 1 mg | 15 | $16,736 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 63 | $14,831 | $28 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 39 | $13,335 | $69 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 69 | $12,383 | $172 |
| Injection of drug or substance under skin or into muscle | 101 | $11,757 | $24 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 17 | $11,268 | $1 |
| Administration of additional new drug or substance into vein, 1 hour or less | 26 | $7,196 | $59 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 39 | $6,189 | $66 |
| Infusion into a vein for hydration, 31-60 minutes | 22 | $6,000 | $55 |
| Drawing of blood for a medical problem | 24 | $5,850 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $5,642 | $62 |
| Administration of chemotherapy into vein, each additional hour | 28 | $5,062 | $27 |
| Injection of additional new drug or substance into vein | 48 | $5,019 | $21 |
| Biopsy of bone marrow | 27 | $4,443 | $159 |
| Administration of additional new drug or substance into vein using push technique | 18 | $4,266 | $60 |
| Injection, carboplatin, 50 mg | 22 | $2,635 | None |
| Aspiration of bone marrow sample for diagnosis | 27 | $2,189 | $78 |
| Injection of drug or substance into vein | 26 | $2,187 | $55 |
| Irrigation of implanted venous access drug delivery device | 26 | $1,955 | $23 |
| Infusion into a vein for hydration, each additional hour | 14 | $927 | $14 |
| Insertion of needle into vein for collection of blood sample | 195 | $803 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 54 | $280 | None |
| Infusion, normal saline solution , 1000 cc | 23 | $193 | None |
| Injection, ranitidine hydrochloride, 25 mg | 29 | $191 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 17 | $170 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 46 | $98 | None |
| Stool analysis for blood to screen for colon tumors | 12 | $52 | $4 |
| Injection, ondansetron hydrochloride, per 1 mg | 11 | $32 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 18 | $19 | None |
| Unclassified drugs | 12 | $14 | None |
2015: 41 services
| Injection, pegfilgrastim, 6 mg | 23 | $289,964 | None |
| Injection, denosumab, 1 mg | 40 | $229,562 | None |
| Return visit (30+ min) | 493 | $122,662 | $91 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 23 | $88,231 | None |
| Administration of chemotherapy into vein, 1 hour or less | 58 | $68,606 | $131 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 19 | $44,914 | None |
| Short return visit (20+ min) | 168 | $40,969 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 120 | $39,618 | $90 |
| Injection, palonosetron hcl, 25 mcg | 39 | $32,000 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 45 | $28,369 | $72 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 478 | $21,653 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 65 | $20,639 | $29 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 24 | $18,373 | $1 |
| Long return visit (40+ min) | 104 | $18,189 | $125 |
| New patient visit (60+ min) | 102 | $17,871 | $175 |
| Injection, docetaxel, 1 mg | 12 | $16,279 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 75 | $13,337 | $173 |
| Administration of additional new drug or substance into vein, 1 hour or less | 33 | $10,775 | $60 |
| Injection of drug or substance under skin or into muscle | 68 | $9,995 | $24 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 48 | $9,970 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 43 | $6,241 | $62 |
| Injection of additional new drug or substance into vein | 48 | $5,295 | $21 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 13 | $4,901 | None |
| Infusion into a vein for hydration, 31-60 minutes | 30 | $4,517 | $55 |
| Administration of chemotherapy into vein, each additional hour | 24 | $4,512 | $27 |
| Administration of additional new drug or substance into vein using push technique | 15 | $4,412 | $60 |
| Drawing of blood for a medical problem | 16 | $3,462 | $87 |
| Injection of drug or substance into vein | 19 | $2,193 | $55 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $1,949 | $31 |
| Injection, carboplatin, 50 mg | 14 | $1,895 | None |
| Irrigation of implanted venous access drug delivery device | 28 | $1,854 | $22 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 12 | $1,507 | $18 |
| Infusion into a vein for hydration, each additional hour | 28 | $1,333 | $14 |
| Injection, dexamethasone sodium phosphate, 1 mg | 54 | $374 | None |
| Insertion of needle into vein for collection of blood sample | 89 | $312 | $3 |
| Injection, ranitidine hydrochloride, 25 mg | 35 | $282 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 17 | $176 | None |
| Infusion, normal saline solution , 1000 cc | 34 | $152 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 47 | $128 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 18 | $30 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 20 | $17 | None |
2014: 45 services
| Injection, pegfilgrastim, 6 mg | 23 | $315,239 | None |
| Injection, denosumab, 1 mg | 34 | $224,895 | None |
| Return visit (30+ min) | 474 | $132,564 | $90 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 25 | $83,560 | None |
| Administration of chemotherapy into vein, 1 hour or less | 58 | $62,929 | $128 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 15 | $46,495 | None |
| Injection, palonosetron hcl, 25 mcg | 35 | $33,134 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 124 | $25,522 | $88 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 467 | $21,208 | $10 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 108 | $18,844 | $170 |
| Short return visit (20+ min) | 102 | $18,526 | $65 |
| New patient visit (60+ min) | 107 | $18,082 | $169 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 64 | $16,652 | $28 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 22 | $13,722 | $1 |
| Long return visit (40+ min) | 91 | $12,098 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 85 | $11,038 | $61 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 52 | $10,871 | $65 |
| Injection of drug or substance under skin or into muscle | 61 | $9,942 | $23 |
| Administration of additional new drug or substance into vein, 1 hour or less | 28 | $9,778 | $59 |
| Injection of additional new drug or substance into vein | 55 | $9,441 | $21 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 30 | $8,272 | $71 |
| Administration of additional new drug or substance into vein using push technique | 19 | $6,623 | $59 |
| Infusion into a vein for hydration, 31-60 minutes | 23 | $6,546 | $55 |
| Drawing of blood for a medical problem | 15 | $5,281 | $90 |
| Administration of chemotherapy into vein, each additional hour | 26 | $4,939 | $26 |
| Blood test, comprehensive group of blood chemicals | 151 | $3,925 | $14 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 14 | $2,741 | None |
| Injection of drug or substance into vein | 30 | $2,689 | $53 |
| Aspiration of bone marrow sample for diagnosis | 18 | $2,268 | $119 |
| Infusion into a vein for hydration, each additional hour | 20 | $2,244 | $14 |
| Irrigation of implanted venous access drug delivery device | 25 | $1,961 | $22 |
| Injection, carboplatin, 50 mg | 19 | $1,869 | None |
| Biopsy of bone marrow | 13 | $1,729 | $124 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 18 | $1,286 | $17 |
| Carcinoembryonic antigen (cea) protein level | 19 | $710 | $25 |
| Ferritin (blood protein) level | 24 | $528 | $18 |
| Insertion of needle into vein for collection of blood sample | 128 | $485 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 55 | $469 | None |
| Injection, ranitidine hydrochloride, 25 mg | 34 | $312 | None |
| Infusion, normal saline solution , 1000 cc | 27 | $167 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 53 | $152 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 16 | $133 | None |
| Lactate dehydrogenase (enzyme) level | 22 | $120 | $5 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 16 | $29 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 14 | $20 | None |
2013: 51 services
| Injection, pegfilgrastim, 6 mg | 28 | $238,071 | None |
| Return visit (30+ min) | 352 | $117,889 | $92 |
| Injection, denosumab, 1 mg | 22 | $96,000 | None |
| Administration of chemotherapy into vein, 1 hour or less | 64 | $72,696 | $137 |
| Injection, filgrastim (g-csf), 480 mcg | 21 | $45,449 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 13 | $39,319 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 152 | $37,692 | $86 |
| Injection, palonosetron hcl, 25 mcg | 44 | $32,065 | None |
| Long return visit (40+ min) | 232 | $29,941 | $118 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 122 | $21,524 | $167 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 109 | $17,984 | $60 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 360 | $17,557 | $11 |
| New patient visit (60+ min) | 102 | $17,421 | $171 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 71 | $17,099 | $30 |
| Short return visit (20+ min) | 86 | $15,877 | $62 |
| Zoldedronic acid 1mg | 12 | $14,601 | $135 |
| Administration of additional new drug or substance into vein, 1 hour or less | 38 | $12,094 | $68 |
| Administration of chemotherapy into vein, each additional hour | 52 | $11,338 | $29 |
| Blood test, comprehensive group of blood chemicals | 249 | $9,625 | $14 |
| Injection of drug or substance under skin or into muscle | 70 | $8,894 | $24 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 41 | $6,920 | $71 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $4,561 | None |
| Drawing of blood for a medical problem | 15 | $4,420 | $92 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $3,789 | $71 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 48 | $3,644 | $17 |
| Infusion into a vein for hydration, 31-60 minutes | 21 | $3,125 | $55 |
| Administration of additional new drug or substance into vein using push technique | 15 | $2,615 | $59 |
| Irrigation of implanted venous access drug delivery device | 32 | $2,612 | $23 |
| Carcinoembryonic antigen (cea) protein level | 42 | $2,489 | $26 |
| Biopsy of bone marrow | 11 | $1,706 | $142 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 22 | $1,381 | $20 |
| Injection, carboplatin, 50 mg | 14 | $1,284 | None |
| Injection of additional new drug or substance into vein | 25 | $1,157 | $21 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 49 | $1,079 | None |
| Ferritin (blood protein) level | 38 | $1,070 | $18 |
| Aspiration of bone marrow sample for diagnosis | 11 | $995 | $90 |
| Infusion into a vein for hydration, each additional hour | 17 | $782 | $14 |
| Infusion, normal saline solution , 1000 cc | 67 | $536 | None |
| Lactate dehydrogenase (enzyme) level | 40 | $516 | $7 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 12 | $479 | $28 |
| Cyanocobalamin (vitamin b-12) level | 21 | $470 | $20 |
| Folic acid level, serum | 15 | $399 | $20 |
| Injection, dexamethasone sodium phosphate, 1 mg | 61 | $392 | None |
| Iron binding capacity | 28 | $341 | $9 |
| Iron level | 29 | $324 | $9 |
| Injection, ranitidine hydrochloride, 25 mg | 31 | $267 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 57 | $161 | None |
| Insertion of needle into vein for collection of blood sample | 46 | $156 | $3 |
| Injection, ondansetron hydrochloride, per 1 mg | 16 | $109 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 18 | $19 | None |
| Infusion, normal saline solution, 250 cc | 20 | $16 | None |
Medicaid work
$13,184 in 2024
Medicaid paid $13,184 for 324 billed services this clinician did in 2024, up to 34 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 324 | $13,184 |
| 2024 | 324 | 1 | 34 | $13,184 |
| 2023 | 333 | 2 | 24 | $4,587 |
| 2022 | 169 | 2 | 19 | $3,420 |
| 2021 | 306 | 2 | 23 | $7,301 |
| 2020 | 539 | 4 | 27 | $6,820 |
| 2019 | 787 | 4 | 27 | $6,046 |
| 2018 | 548 | 3 | 27 | $3,537 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 201 | $3,957 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 132 | $630 |
2022
| Return visit (30+ min) | 115 | $3,251 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 54 | $169 |
2021
| Return visit (30+ min) | 193 | $6,885 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 113 | $416 |
2020
| Return visit (30+ min) | 233 | $5,617 |
| Short return visit (20+ min) | 38 | $714 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 217 | $364 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 51 | $124 |
2019
| Return visit (30+ min) | 204 | $3,989 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 399 | $1,118 |
| Short return visit (20+ min) | 38 | $725 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 146 | $214 |
2018
| Return visit (30+ min) | 204 | $3,099 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 323 | $438 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 21 | $1 |
Drugs they prescribed that Part D paid
$554,797
Pharmacies billed $554,797 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
441 generic and fewer than 11 brand-name prescriptions · $554,797 in drug cost · 19 antibiotic prescriptions to 16 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tagrisso | 15 | $251,819 | $16,788 |
| Xarelto | 26 | $28,327 | $1,090 |
| Eliquis | 18 | $26,294 | $1,461 |
| Anastrozole | 71 | $1,628 | $23 |
| Letrozole | 48 | $1,138 | $24 |
See all 12 drugs
| Tagrisso | 15 | $251,819 | $16,788 |
| Xarelto | 26 | $28,327 | $1,090 |
| Eliquis | 18 | $26,294 | $1,461 |
| Anastrozole | 71 | $1,628 | $23 |
| Letrozole | 48 | $1,138 | $24 |
| Gabapentin | 35 | $426 | $12 |
| Mirtazapine | 15 | $414 | $28 |
| Alendronate | 35 | $363 | $10 |
| Tamoxifen Citrate | 26 | $332 | $13 |
| Ondansetron | 12 | $156 | $13 |
| Levothyroxine | 13 | $108 | $8 |
| Prednisone | 12 | $59 | $5 |
Year by year
| 2024 | 527 | 202 | None | None | $554,797 |
| 2023 | 468 | 185 | 3% (15) | None | $382,791 |
| 2022 | 458 | 169 | None | 15% | $243,477 |
| 2021 | 450 | 167 | 6% (27) | 18% | $292,803 |
| 2020 | 566 | 188 | 3% (18) | 20% | $505,819 |
| 2019 | 1,083 | 219 | 3% (36) | 20% | $1,887,754 |
| 2018 | 1,473 | 253 | 8% (112) | None | $2,250,249 |
| 2017 | 1,283 | 231 | 4% (56) | 21% | $2,019,799 |
| 2016 | 1,414 | 223 | 3% (48) | 17% | $1,249,281 |
| 2015 | 1,142 | 205 | 7% (76) | None | $1,198,984 |
| 2014 | 1,221 | 179 | 14% (171) | None | $1,091,241 |
| 2013 | 1,054 | 177 | 14% (146) | 15% | $491,345 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Xarelto | 26 | $28,424 | $1,093 |
| Eliquis | 20 | $16,270 | $813 |
| Anastrozole | 69 | $3,029 | $44 |
| Letrozole | 37 | $1,988 | $54 |
| Alendronate | 36 | $505 | $14 |
| Tamoxifen Citrate | 11 | $297 | $27 |
| Prednisone | 19 | $218 | $11 |
| Gabapentin | 15 | $145 | $10 |
| Furosemide | 11 | $58 | $5 |
2022: 11 drugs
| Xarelto | 25 | $32,309 | $1,292 |
| Eliquis | 29 | $22,335 | $770 |
| Anastrozole | 94 | $2,426 | $26 |
| Letrozole | 28 | $1,273 | $45 |
| Hydroxyurea | 17 | $935 | $55 |
| Dexamethasone | 16 | $442 | $28 |
| Mirtazapine | 16 | $438 | $27 |
| Alendronate | 37 | $423 | $11 |
| Tamoxifen Citrate | 18 | $375 | $21 |
| Prednisone | 16 | $233 | $15 |
| Gabapentin | 11 | $105 | $10 |
2021: 9 drugs
| Xarelto | 20 | $18,060 | $903 |
| Eliquis | 19 | $11,873 | $625 |
| Exemestane | 15 | $3,429 | $229 |
| Anastrozole | 81 | $2,192 | $27 |
| Letrozole | 23 | $995 | $43 |
| Hydroxyurea | 12 | $815 | $68 |
| Alendronate | 36 | $288 | $8 |
| Duloxetine | 13 | $241 | $19 |
| Prednisone | 19 | $161 | $8 |
2020: 12 drugs
| Ibrance | 22 | $296,508 | $13,478 |
| Xarelto | 35 | $27,479 | $785 |
| Eliquis | 20 | $12,345 | $617 |
| Exemestane | 23 | $8,124 | $353 |
| Anastrozole | 89 | $2,656 | $30 |
| Hydroxyurea | 36 | $1,782 | $50 |
| Letrozole | 37 | $1,531 | $41 |
| Dexamethasone | 11 | $489 | $44 |
| Mirtazapine | 13 | $407 | $31 |
| Prednisone | 28 | $319 | $11 |
| Alendronate | 23 | $244 | $11 |
| Lorazepam | 15 | $48 | $3 |
2019: 26 drugs
| Revlimid | 51 | $875,909 | $17,175 |
| Ibrance | 33 | $402,713 | $12,203 |
| Imatinib Mesylate | 23 | $36,337 | $1,580 |
| Xarelto | 49 | $28,131 | $574 |
| Exemestane | 39 | $12,521 | $321 |
| Anastrozole | 143 | $3,992 | $28 |
| Letrozole | 67 | $2,223 | $33 |
| Tamoxifen Citrate | 32 | $1,836 | $57 |
| Hydroxyurea | 33 | $1,463 | $44 |
| Dexamethasone | 38 | $1,088 | $29 |
| Ondansetron | 33 | $949 | $29 |
| Hydrocodone-Acetaminophen | 22 | $808 | $37 |
| Gabapentin | 14 | $562 | $40 |
| Mirtazapine | 12 | $554 | $46 |
| Acyclovir | 27 | $486 | $18 |
| Pantoprazole | 20 | $472 | $24 |
| Omeprazole | 20 | $284 | $14 |
| Prednisone | 16 | $239 | $15 |
| Alendronate | 19 | $226 | $12 |
| Warfarin | 17 | $211 | $12 |
| Escitalopram | 12 | $201 | $17 |
| Lorazepam | 24 | $188 | $8 |
| Prochlorperazine Maleate | 15 | $146 | $10 |
| Trazodone | 22 | $139 | $6 |
| Zolpidem | 11 | $72 | $7 |
| Furosemide | 12 | $62 | $5 |
2018: 36 drugs
| Revlimid | 64 | $977,968 | $15,281 |
| Ibrance | 24 | $273,370 | $11,390 |
| Afinitor | 11 | $155,309 | $14,119 |
| Xtandi | 12 | $139,830 | $11,653 |
| Jakafi | 12 | $124,514 | $10,376 |
| Imatinib Mesylate | 15 | $50,757 | $3,384 |
| Exemestane | 59 | $22,641 | $384 |
| Xarelto | 34 | $18,957 | $558 |
| Anastrozole | 191 | $4,463 | $23 |
| Dexilant | 11 | $4,327 | $393 |
| Tamoxifen Citrate | 48 | $2,828 | $59 |
| Dexamethasone | 46 | $1,933 | $42 |
| Ondansetron | 34 | $1,791 | $53 |
| Hydroxyurea | 43 | $1,710 | $40 |
| Fentanyl | 18 | $1,324 | $74 |
| Hydrocodone-Acetaminophen | 37 | $1,250 | $34 |
| Letrozole | 60 | $1,094 | $18 |
| Ventolin Hfa | 12 | $686 | $57 |
| Warfarin | 45 | $654 | $15 |
| Oxycodone | 16 | $627 | $39 |
| Prednisone | 51 | $582 | $11 |
| Acyclovir | 34 | $536 | $16 |
| Lidocaine-Prilocaine | 20 | $478 | $24 |
| Pantoprazole | 25 | $477 | $19 |
| Escitalopram | 32 | $466 | $15 |
| Morphine Sulfate Er | 14 | $460 | $33 |
| Alendronate | 37 | $342 | $9 |
| Mirtazapine | 28 | $330 | $12 |
| Venlafaxine Hcl Er | 20 | $260 | $13 |
| Duloxetine | 19 | $218 | $11 |
| Bupropion Hcl Sr | 11 | $215 | $20 |
| Omeprazole | 26 | $210 | $8 |
| Gabapentin | 17 | $179 | $11 |
| Lorazepam | 22 | $105 | $5 |
| Tramadol | 11 | $72 | $7 |
| Trazodone | 18 | $69 | $4 |
2017: 30 drugs
| Revlimid | 56 | $831,124 | $14,841 |
| Promacta | 15 | $200,740 | $13,383 |
| Xtandi | 16 | $161,737 | $10,109 |
| Imbruvica | 15 | $138,590 | $9,239 |
| Xarelto | 49 | $22,475 | $459 |
| Exemestane | 44 | $21,316 | $484 |
| Anastrozole | 257 | $4,897 | $19 |
| Lyrica | 14 | $2,894 | $207 |
| Fentanyl | 17 | $2,785 | $164 |
| Tamoxifen Citrate | 46 | $2,033 | $44 |
| Hydroxyurea | 30 | $1,086 | $36 |
| Megestrol Acetate | 12 | $617 | $51 |
| Letrozole | 42 | $605 | $14 |
| Warfarin | 35 | $559 | $16 |
| Hydrocodone-Acetaminophen | 20 | $461 | $23 |
| Ondansetron | 21 | $378 | $18 |
| Venlafaxine Hcl Er | 26 | $367 | $14 |
| Duloxetine | 22 | $337 | $15 |
| Dexamethasone | 14 | $322 | $23 |
| Prednisone | 28 | $314 | $11 |
| Alendronate | 36 | $308 | $9 |
| Pantoprazole | 18 | $306 | $17 |
| Acyclovir | 12 | $279 | $23 |
| Bupropion Hcl Sr | 12 | $234 | $20 |
| Jantoven | 15 | $232 | $15 |
| Gabapentin | 26 | $179 | $7 |
| Lorazepam | 29 | $151 | $5 |
| Mirtazapine | 20 | $146 | $7 |
| Furosemide | 18 | $95 | $5 |
| Tramadol | 12 | $74 | $6 |
2016: 28 drugs
| Revlimid | 32 | $368,819 | $11,526 |
| Promacta | 16 | $184,056 | $11,504 |
| Afinitor | 14 | $162,260 | $11,590 |
| Zytiga | 11 | $95,255 | $8,660 |
| Xarelto | 70 | $29,216 | $417 |
| Exemestane | 32 | $9,031 | $282 |
| Enoxaparin | 13 | $4,854 | $373 |
| Anastrozole | 270 | $4,772 | $18 |
| Tamoxifen Citrate | 67 | $2,248 | $34 |
| Hydroxyurea | 52 | $1,849 | $36 |
| Ondansetron | 57 | $1,137 | $20 |
| Letrozole | 40 | $993 | $25 |
| Hydrocodone-Acetaminophen | 21 | $766 | $36 |
| Warfarin | 51 | $696 | $14 |
| Duloxetine | 23 | $666 | $29 |
| Prednisone | 58 | $581 | $10 |
| Gabapentin | 39 | $477 | $12 |
| Diphenoxylate-Atropine | 18 | $466 | $26 |
| Lidocaine-Prilocaine | 16 | $442 | $28 |
| Lorazepam | 37 | $373 | $10 |
| Dexamethasone | 26 | $320 | $12 |
| Alendronate | 34 | $314 | $9 |
| Venlafaxine Hcl Er | 16 | $211 | $13 |
| Jantoven | 19 | $206 | $11 |
| Acyclovir | 12 | $180 | $15 |
| Omeprazole | 24 | $175 | $7 |
| Prochlorperazine Maleate | 12 | $107 | $9 |
| Furosemide | 14 | $36 | $3 |
2015: 26 drugs
| Revlimid | 40 | $409,414 | $10,235 |
| Gleevec | 13 | $127,215 | $9,786 |
| Zytiga | 13 | $99,251 | $7,635 |
| Exemestane | 39 | $14,172 | $363 |
| Xarelto | 21 | $8,333 | $397 |
| Anastrozole | 164 | $3,382 | $21 |
| Fentanyl | 25 | $2,654 | $106 |
| Tamoxifen Citrate | 47 | $1,892 | $40 |
| Ondansetron | 33 | $1,870 | $57 |
| Hydroxyurea | 32 | $1,397 | $44 |
| Duloxetine | 25 | $1,297 | $52 |
| Letrozole | 42 | $1,096 | $26 |
| Hydrocodone-Acetaminophen | 29 | $1,067 | $37 |
| Warfarin | 71 | $955 | $13 |
| Ondansetron Odt | 20 | $394 | $20 |
| Lorazepam | 45 | $383 | $9 |
| Venlafaxine Hcl Er | 23 | $315 | $14 |
| Gabapentin | 37 | $282 | $8 |
| Levothyroxine | 18 | $266 | $15 |
| Prednisone | 40 | $251 | $6 |
| Omeprazole | 14 | $161 | $11 |
| Dexamethasone | 16 | $156 | $10 |
| Alendronate | 11 | $90 | $8 |
| Prochlorperazine Maleate | 11 | $74 | $7 |
| Levofloxacin | 13 | $60 | $5 |
| Furosemide | 14 | $33 | $2 |
2014: 31 drugs
| Revlimid | 40 | $386,396 | $9,660 |
| Gleevec | 14 | $183,748 | $13,125 |
| Zytiga | 11 | $78,073 | $7,098 |
| Promacta | 12 | $68,405 | $5,700 |
| Neupogen | 22 | $10,482 | $476 |
| Exemestane | 22 | $7,506 | $341 |
| Xarelto | 24 | $7,240 | $302 |
| Anastrozole | 143 | $5,775 | $40 |
| Fentanyl | 46 | $5,216 | $113 |
| Lyrica | 13 | $3,638 | $280 |
| Anagrelide | 12 | $2,034 | $170 |
| Tamoxifen Citrate | 73 | $2,002 | $27 |
| Hydrocodone-Acetaminophen | 60 | $1,660 | $28 |
| Morphine Sulfate Er | 12 | $1,464 | $122 |
| Ondansetron | 57 | $1,462 | $26 |
| Hydroxyurea | 29 | $1,347 | $46 |
| Calcitonin-Salmon | 11 | $1,046 | $95 |
| Letrozole | 38 | $1,028 | $27 |
| Warfarin | 70 | $785 | $11 |
| Oxycodone-Acetaminophen | 17 | $759 | $45 |
| Acetaminophen-Codeine | 20 | $272 | $14 |
| Lorazepam | 42 | $261 | $6 |
| Prednisone | 29 | $257 | $9 |
| Lidocaine-Prilocaine | 11 | $248 | $23 |
| Omeprazole | 31 | $241 | $8 |
| Diphenoxylate-Atropine | 18 | $225 | $13 |
| Dexamethasone | 17 | $214 | $13 |
| Tamsulosin | 11 | $209 | $19 |
| Gabapentin | 17 | $180 | $11 |
| Prochlorperazine Maleate | 12 | $93 | $8 |
| Furosemide | 14 | $59 | $4 |
2013: 29 drugs
| Stivarga | 20 | $194,063 | $9,703 |
| Promacta | 12 | $43,800 | $3,650 |
| Enoxaparin | 13 | $7,817 | $601 |
| Anastrozole | 95 | $4,893 | $52 |
| Fentanyl | 22 | $4,368 | $199 |
| Exemestane | 11 | $2,677 | $243 |
| Hydrocodone-Acetaminophen | 54 | $1,637 | $30 |
| Ondansetron | 45 | $1,339 | $30 |
| Hydroxyurea | 31 | $1,180 | $38 |
| Letrozole | 17 | $1,069 | $63 |
| Tamoxifen Citrate | 45 | $970 | $22 |
| Warfarin | 53 | $505 | $10 |
| Lidocaine-Prilocaine | 16 | $407 | $25 |
| Mirtazapine | 39 | $385 | $10 |
| Prochlorperazine Maleate | 30 | $274 | $9 |
| Methadone | 11 | $217 | $20 |
| Hydromorphone | 12 | $215 | $18 |
| Omeprazole | 12 | $198 | $16 |
| Zolpidem | 21 | $178 | $8 |
| Amlodipine Besylate | 14 | $176 | $13 |
| Alendronate | 11 | $170 | $15 |
| Acetaminophen-Codeine | 14 | $163 | $12 |
| Dexamethasone | 18 | $162 | $9 |
| Prednisone | 28 | $156 | $6 |
| Lorazepam | 26 | $145 | $6 |
| Lisinopril | 16 | $132 | $8 |
| Ciprofloxacin | 22 | $113 | $5 |
| Gabapentin | 12 | $111 | $9 |
| Diphenoxylate-Atropine | 11 | $89 | $8 |
Money from drug and device companies
$241 in 2025
| 2025 | 5 | 6 | None | $241 |
| 2024 | 8 | 10 | None | $250 |
| 2023 | 11 | 25 | None | $511 |
| 2022 | 7 | 10 | None | $185 |
| 2021 | 4 | 14 | None | $223 |
| 2020 | 2 | 3 | None | $57 |
| 2019 | 1 | 1 | None | $13 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | General - Therapies | $112 | 1 payment
|
| Gilead Sciences | Trodelvy | $45 | 2 payments
|
| Pfizer | Ibrance | $31 | 1 payment
|
| Abbvie | Imbruvica | $28 | 1 payment
|
| Teleflex | Arrow | $25 | 1 payment
|
See all 6 published payments
| Abbvie | Meals · 2025-12-04 | Imbruvica | $28 |
| Boston Scientific | Meals · 2025-11-06 | General - Therapies | $112 |
| Gilead Sciences | Meals · 2025-11-01 | Trodelvy | $18 |
| Gilead Sciences | Meals · 2025-10-23 | Trodelvy | $27 |
| Pfizer | Education · 2025-10-08 | Ibrance | $31 |
| Teleflex | Meals · 2025-06-25 | Arrow | $25 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $250
| Merck Sharp & Dohme | Keytruda | $56 | 2 payments
|
| Gilead Sciences | None | $40 | 2 payments
|
| Janssen Biotech | Erleada | $39 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $26 | 1 payment
|
| Celgene | None | $26 | 1 payment
|
| ADC Therapeutics America | None | $24 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $20 | 1 payment
|
| Pfizer | Inlyta | $18 | 1 payment
|
2023: $511
| Pfizer | Ibrance | $173 | 11 payments
|
| Amgen | Evenity | $80 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $63 | 2 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $46 | 2 payments
|
| Seagen | Tukysa | $28 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $23 | 1 payment
|
| Stemline Therapeutics | Orserdu | $23 | 1 payment
|
| PharmaEssentia USA | Besremi | $22 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $19 | 1 payment
|
| Daiichi Sankyo | Enhertu | $18 | 1 payment
|
| Coherus Biosciences | Udenyca | $16 | 1 payment
|
2022: $185
| Seagen | Tukysa | $42 | 2 payments
|
| GlaxoSmithKline | Blenrep | $35 | 1 payment
|
| Acrotech Biopharma | Beleodaq | $26 | 2 payments
|
| Coherus Biosciences | Udenyca | $25 | 2 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $23 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $22 | 1 payment
|
| Janssen Pharmaceuticals | None | $12 | 1 payment
|
2021: $223
| Pfizer | Inlyta | $145 | 10 payments
|
| Janssen Biotech | Imbruvica | $40 | 2 payments
|
| Genentech USA | None | $23 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $15 | 1 payment
|
2020: $57
| Janssen Biotech | Darzalex | $30 | 1 payment
|
| Pfizer | Inlyta | $27 | 2 payments
|
2019: $13
| Pfizer | Braftovi | $13 | 1 payment
|
Professional record
- NPI
- 1053450767
- Licence
- CA A93219California A93219: Current · expires 2027-11-30
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0000X (207RH0000X); Federal specialty code 207RH0002X (207RH0002X); Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 5725 W Las Positas Blvd Ste 100a, Pleasanton, CA, 94588
- NPI first listed
- 2007-02-06
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.